RecruitingPhase 1NCT07580898

Safety of MOON101 for the Treatment of Peanut Allergy


Sponsor

Moonlight Therapeutics, Inc.

Enrollment

40 participants

Start Date

Jun 29, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this open-label, single escalating dose study in 3 sequential groups: adults, adolescents, and children with peanut allergy is to assess the safety of MOON101. The main question it aims to answer is: 1. the incidence and frequency of all treatment emergent adverse events (TEAEs) from baseline through study exit. 2. to determine the highest tolerated dose for each participant, as defined by the highest MOON101 dose level administered which did not cause a dose-limiting symptom (DLS). The study will compare MOON101 and placebo. All participants will receive both active MOON101 (peanut allergen) and placebo (no peanut allergen).


Eligibility

Min Age: 4 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Dose A, Dose B, and others for people with peanut allergy. The study is currently recruiting participants at 5 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTDose A

MOON101-1 is a microneedle stamp (a square stainless steel array) coated with 1 ug of peanut extract (active drug).

COMBINATION_PRODUCTDose B

MOON101-10 is a microneedle stamp (a square stainless steel array) coated with 10 ug of peanut extract (active drug).

COMBINATION_PRODUCTDose C

MOON101-25 is a microneedle stamp (a square stainless steel array) coated with 25 ug of peanut extract (active drug).

COMBINATION_PRODUCTDose D

MOON101-50 is a microneedle stamp (a square stainless steel array) coated with 50 ug of peanut extract (active drug).

COMBINATION_PRODUCTDose E

MOON101-100 is two microneedle stamps (a square stainless steel array) coated with 50 ug of peanut extract (active drug) each. Two stamps are used to administer a 100ug dose of peanut extract in Dose E.

COMBINATION_PRODUCTPlacebo

MOON101-0 is a microneedle stamp (a square stainless steel array) coated with 0 ug of peanut extract (active drug). There is no peanut extract on the MOON101-0 stamp.


Locations(5)

Arkansas Children's Research Institute

Little Rock, Arkansas, United States

Children's Healthcare of Atlanta

Atlanta, Georgia, United States

Dr. Vince Clinical Research

Overland Park, Kansas, United States

University of Michigan

Ann Arbor, Michigan, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07580898


Related Trials